A preliminary study to examine and evaluate the effect of obeticholic acid (INT-747) for the treatment of portal hypertension in patients with alcoholic liver disease

ISRCTN ISRCTN22662520
DOI https://doi.org/10.1186/ISRCTN22662520
EudraCT/CTIS number 2010-023241-29
Secondary identifying numbers 747-204
Submission date
05/05/2011
Registration date
15/07/2011
Last edited
28/05/2020
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Rajeshwar Mookerjee
Scientific

Department of Hepatology
Royal Free Hospital
Pond Street
Hampstead
London
NW3 2QG
United Kingdom

Phone +44 (0)207 433 2874
Email r.mookerjee@ucl.ac.uk

Study information

Study designPilot open-label single-centre study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleA pilot study to evaluate the safety, tolerability and efficacy of obeticholic acid (INT-747) for the treatment of portal hypertension
Study acronymPESTO
Study objectives1. Obeticholic acid (OCA) is safe and tolerated in patients with cirrhosis and portal hypertension
2. Obeticholic acid (OCA) will reduce the Hepatic Venous Pressure Gradient (HVPG) in patients with portal hypertension
Ethics approval(s)National Research Ethics Service (NRES) North London REC 3 Committee approval granted on:
10/12/2010 (Final Protocol)
01/03/2011 (Amendment 1)
05/04/2011 (Amendment 2)
02/12/2011 (Amendment 3)
Health condition(s) or problem(s) studiedPortal hypertension in patients with alcoholic cirrhosis of the liver
Intervention1. Physical examination
2. Vital signs
3. 12-lead electrocardiogram (ECG)
4. Blood sampling and analysis – peripheral and hepatic blood samples
5. Urine collection and analysis
6. Hepatic vein catheterisation to measure HVPG and other hepatic haemodynamic measures (efficacy cohort only)
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Obeticholic acid (OCA)
Primary outcome measure1. Safety and tolerability as measured and assessed throughout the study by monitoring adverse experiences, clinical laboratory values in blood and measures of blood pressure and heart rate, all at baseline, Day 4, Day 7 and at follow up after 2-4 weeks and ECG at baseline and Day 7
2. Portal hypertension measured at baseline and Day 7 by HPVG. Outcome measure of a reduction of ≥15% at Day 7 compared to baseline or a reduction to <12 mmHg
Secondary outcome measures1. Hepatic haemodynamics including hepatic blood flow (measured from the concentration of indocynanine green in the hepatic venous blood vs peripheral venous blood using the Fick Principle) and intrahepatic resistance (fluoroscopic examination after catheterisation of the right hepatic vein following injection of contrast medium)
2. Liver function: measured by gamma glutamyl transpeptidase (GGT), alanine transaminase (ALT), alkaline phosphatase (ALP), albumin, prothrombin time and bilirubin (total and unconjugated)
3. Pharmacokinetics: measured by plasma drug and metabolite concentrations
4. Inflammation: measured by C-reactive protein
Overall study start date01/07/2011
Completion date31/12/2012

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit70 Years
SexBoth
Target number of participantsUp to 39, depending on number of cohorts studied (3 cohorts up to 39, 2 cohorts up to 26)
Total final enrolment34
Key inclusion criteria1. Male or female age 18-70 years
2. History of alcoholic cirrhosis with clinical or radiological and biochemical evidence of cirrhosis
3. Evidence of early decompensated cirrhosis (Child-Pugh score ≥7 to ≤12)
4. Patients recruited into the cohort evaluation of efficacy must have significant portal hypertension defined as an HVPG ≥ 12 mmHg
5. Patients with large or grade 3 oesophageal varices as identified by endoscopy within 6 months of screening should be in an endoscopic band ligation program at the time of study entry
6. Female patients must be postmenopausal, surgically sterile, or if premenopausal, must be prepared to use at least one effective (≤1% failure rate) method of contraception during the course of the study and for 14 days after the end of dosing. Male patients with female partners of child bearing potential must be prepared to use at least one effective method of contraception with all sexual partners unless they have had a prior vasectomy. Effective methods of contraception are considered to be:
6.1. Condom (male or female)
6.2. Diaphragm, with spermicide
6.3. Hormonal (e.g. contraceptive pill, patch, intramuscular implant or injection)
6.4. Intrauterine device (IUD)
6.5. Vasectomy (partner)
7. Must be willing and able to give written informed consent and agree to comply with the study protocol
Key exclusion criteria1. Patients with co-existing disease including:
1.1. Significant organ failure defined as:
1.2. Respiratory: PaO2 < 8kPa
1.3. Renal: serum creatinine >150 μmol/L
1.4. Cardiovascular: haemodynamic requirement for inotropic support
1.5. Central nervous system (CNS): hepatic encephalopathy West Haven Criteria score >2
1.6. Decompensated cirrhosis with requirement for organ support
1.7. Concomitant hepatobiliary disease (except hepatitis B or C viral disease), e.g., gallstones, primary sclerosing cholangitis, primary biliary cirrhosis
1.8. Known or suspected hepatic or extra hepatic malignancy, unless adequately treated or in complete remission for ≥ 3 years
1.9. Concomitant pancreatitis
2. Use of treatments for hepatitis B or C virus within 12 months of randomisation, or anticipated use during the study
3. Use of the following drugs within 6 months of randomisation: Immuno-modulatory treatment (including azothiaprine, methotrexate, anti-TNF therapies)
4. Use of concomitant vasoactive drugs within 3 months of randomisation:
4.1. Beta blockers
4.2. Nitrates
4.3. Vasopressin or analogues
5. Use of the following drugs within 3 months of randomisation:
5.1. Systemic corticosteroids
5.2. Pentoxifylline
5.3. Potentially hepatotoxic drugs (including  methyl-dopa, sodium valproic acid, isoniazid, or nitrofurantoin)
5.4. Ursodeoxycholic acid (UDCA)
5.5. Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated)
6. Change in dose or regimen within 3 months of randomisation of:
6.1. Fibrates or statins
6.2. Angiotensin II receptor antagonist or angiotensin converting enzyme (ACE) inhibitor
7. Presence of human immunodeficiency virus (HIV)
8. If female: pregnant, lactating, or positive serum or urine pregnancy test
9. Body mass index (BMI) >40, or >35 with complications
10. Other concomitant disease or condition likely to significantly decrease life expectancy (e.g., moderate to severe congestive heart failure)
11. Any patient who has received any investigational drug or device within 4 months of dosing, or who is scheduled to receive another investigational drug or device during the course of this study
Date of first enrolment01/07/2011
Date of final enrolment31/12/2012

Locations

Countries of recruitment

  • Belgium
  • England
  • United Kingdom

Study participating centres

Department of Hepatology, Royal Free Hospital
Pond Street
Hampstead
London
NW3 2QG
United Kingdom
University Hospital Leuven (Universitat Ziekenhuis Leuven (UZL))
Dept Hepatology and Pancreaticobiliary Disorders
Herestraat 49
Leuven
B - 3000
Belgium

Sponsor information

Intercept Pharmaceuticals Inc
Industry

18 Desbrosses Street
New York
NY 10013
United States of America

Phone +1 646 747 1000
Email TBeecherJones@interceptpharma.com
Website http://www.interceptpharma.com
ROR logo "ROR" https://ror.org/01sx6jc36

Funders

Funder type

Industry

Intercept Pharmaceuticals Inc

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planAdded 23/03/2018:
Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver in April 2014 (http://www.professionalabstracts.com/ilc2014/planner/index.php?go=abstract&action=abstract_show&absno=3124&;)
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Basic results 28/05/2020 No No

Editorial Notes

28/05/2020: The following changes were made to the trial record:
1. Added clinicaltrialsregister.eu link to basic results (scientific).
2. The total final enrollment was added.
23/03/2018: No publications found, verifying study status with principal investigator.
26/02/2016: No publications found, verifying study status with principal investigator.